如否，请详细说明：____________________________ 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得 担任公司董事的情形。 证券代码：002688 证券简称：金河生物 公告编号： 2024-109 金河生物科技股份有限公司 ☑ 是 □ 否 独立董事提名人声明与承诺 提名人金河生物科技股份有限公司董事会现就提名郭晓川为金河生物科 技股份有限公司第六届董事会独立董事候选人发表公开声明。被提名人已书 面同意作为金河生物科技股份有限公司第六届董事会独立董事候选人（参见该 独立董事候选人声明）。本次提名是在充分了解被提名人职业、学历、职称、 详细的工作经历、全部兼职、有无重大失信等不良记录等情况后作出的，本 提名人认为被提名人符合相关法律、行政法规、部门规章、规范 性文件和深 圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声 明并承诺如下事项： 一、被提名人已经通过金河生物科技股份有限公司第六届董事会提名委 员会或者独立董事专门会议资格审查，提名人与被提名人不存在利害关系或 者其他可能影响独立履职 情形的密切关系。 1 如否，请详细说明：___________ ...

2、独立董事候选人郭晓川先生任职资格、教育背景、工作经历、业务能力 等符合公司独立董事任职要求，不存在相关法律法规、规章制度规定的不得担任 任上市公司独立董事的情形，不存在被中国证监会确定为市场禁入者且禁入尚未 解除的情形，不存在重大失信等不良记录，也未曾受到中国证监会和深圳证券交 易所的任何处罚和惩戒，具备担任上市公司独立董事的履职能力。 金河生物科技股份有限公司 第六届董事会提名委员会 关于独立董事候选人任职资格的审查意见 根据《中华人民共和国公司法》《上市公司独立董事管理办法》《深圳证券 交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法律、 法规和规范性文件及《公司章程》《独立董事制度》《董事会提名委员会议事规 则》的有关规定，我们作为金河生物科技股份有限公司（以下简称"公司"）第 六届董事会提名委员会成员，对拟提交公司第六届董事会第二十一次会议审议的 《关于公司增补独立董事的议案》进行了认真的审阅，对独立董事候选人的任职 条件和任职资格等相关材料进行了审核，发表审查意见如下： 1、独立董事候选人郭晓川先生具备《上市公司独立董事管理办法》《深圳 证券交易所上市公司自律监管指引第 1 ...

本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）董事会获悉，公司独立 董事姚民仆先生于 2024 年 11 月 7 日不幸因病去世。 姚民仆先生在担任公司董事会独立董事、战略委员会委员、提名委员会委 员、审计委员会委员、薪酬与考核委员会召集人期间，恪尽职守，勤勉尽责， 忠实地履行了作为独立董事应尽的职责和义务，为公司相关决策事项提供了专 业意见和建议，积极维护中小股东利益。公司及公司董事会对姚民仆先生表示 衷心感谢。 姚民仆先生逝世后，公司现任董事会成员由 9 名变为 8 名，未低于法定最 低人数，但低于《公司章程》规定的董事会成员人数和独立董事人数，公司独 立董事人数低于董事会成员的三分之一。公司将根据《公司法》、《公司章程》 等有关规定，尽快按照相关程序增补新的独立董事。在新任独立董事选举完成 之前，公司独立董事职责暂由卢文兵先生和谢晓燕女士两位独立董事履行。公 司的生产经营活动不会因此受到影响。 证券代码：002688 证券简称：金河生物 公告编号：2024-105 金河生物科技股份有限公司 关于公 ...

证券代码：002688 证券简称：金河生物 公告编号：2024-104 金河生物科技股份有限公司 关于农业部批准公司申报的兽药产品变更注册的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 近日，金河生物科技股份有限公司（以下简称"公司"）收到中华人民共 和国农业农村部（以下简称"农业部"）公告第 839 号文件，根据《兽药管理 条例》和《兽药注册办法》规定，经审查批准公司申报的金霉素预混剂兽药产 品变更注册，发布修订后的说明书和标签，自发布之日起执行。详情如下： 一、基本情况 特此公告。 金河生物科技股份有限公司 董 事 会 2024 年 10 月 31 日 兽药标准来源：农业农村部公告第 246 号同品种相应内容 变更事项：增加靶动物绵羊羔羊 监测期（针对变更事项）：3 年 适应证：用于治疗 40 日龄左右绵羊羔羊大肠埃希菌性腹泻；用于治疗断奶 仔猪腹泻；治疗猪气喘病、增生性肠炎等。 二、对公司的影响 公司本次获得批准的金霉素预混剂兽药产品增加靶动物绵羊羔羊是公司持 续注重技术创新和研发工作取得的重要成果，将增加公司产品金霉素预混剂的 适用 ...

证券代码： 002688 证券简称：金河生物 金河生物科技股份有限公司投资者关系活动记录表 编号：2024-006 | --- | --- | --- | |------------------------------|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 √ | 业绩说明会 | | 类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 □ 其他 | （请文字说明其他活动内容） 天风证券、浙商基金、天风国际证券、光大保德信基金、上海五 | | 参与单位名称及 人员姓名 | ...

Core Viewpoint - Jinhe Biological reported a significant increase in net profit and revenue for Q3 2024, driven by strong demand from major clients and international market expansion [1][2] Financial Performance - For the first three quarters of 2024, the company achieved revenue of 1.657 billion yuan, a year-on-year increase of 5.57% [1] - The net profit attributable to shareholders reached 114 million yuan, up 10.38% year-on-year [1] - Operating cash flow amounted to 380 million yuan, reflecting a substantial growth of 122.90% [1] - In Q3 alone, the net profit attributable to shareholders was 22.74 million yuan, marking a 65.92% increase compared to the same period last year [1] Business Segments - The company focuses on animal health, with a dual-driven model of veterinary pharmaceuticals and vaccines, supported by environmental protection and agricultural product processing [1] - In the veterinary pharmaceutical sector, Jinhe Biological is the largest producer of feed-grade chlortetracycline globally, with an annual production capacity of 55,000 tons [1] - The company is expanding its production capacity with a new project that will add 60,000 tons of capacity [1] - The vaccine segment includes competitive product lines for pigs, ruminants, pets, and diagnostic reagents, with 16 products already on the market and over 20 in development [1] Market Expansion - Jinhe Biological is actively expanding its international market presence, with a sales network covering key global markets, particularly in the United States, Canada, Mexico, South America, Europe, Southeast Asia, India, and Vietnam [1] - The company aims to leverage synergies by expanding its veterinary pharmaceutical sales network to include veterinary vaccines [2] - The company aspires to become a technology-driven, scale-leading animal health company within the next 5-10 years, providing high-quality products and services to global customers [2]

Financial Performance - The company's revenue for Q3 2024 was ¥591,527,500.46, representing a 10.08% increase compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥22,740,808.57, a significant increase of 65.92% year-over-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,597,872.51, up 48.13% from the previous year[2]. - The basic earnings per share for Q3 2024 was ¥0.0294, reflecting a 67.05% increase compared to the same quarter last year[2]. - Total operating revenue for Q3 2024 reached ¥1,657,273,697.64, an increase of 5.5% compared to ¥1,569,845,460.39 in the same period last year[28]. - The net profit for Q3 2024 was approximately ¥113.07 million, a slight decrease from ¥113.86 million in Q3 2023, representing a decline of about 0.7%[29]. - Operating profit for Q3 2024 increased to ¥125.34 million, compared to ¥119.12 million in the same period last year, marking an increase of approximately 5.5%[29]. - The company reported a total comprehensive income of ¥106.27 million for Q3 2024, down from ¥125.75 million in Q3 2023, a decrease of about 15.5%[30]. - Basic and diluted earnings per share for Q3 2024 were both ¥0.1461, an increase from ¥0.1321 in Q3 2023, representing a growth of approximately 22.6%[30]. Assets and Liabilities - The total assets at the end of Q3 2024 amounted to ¥5,737,889,958.39, an increase of 5.21% from the end of the previous year[2]. - The company's total assets reached ¥5,737,889,958.39, up from ¥5,453,807,416.04, indicating a growth of 5.2%[27]. - Current liabilities decreased to ¥1,878,369,713.89 from ¥2,257,325,331.09, a reduction of 16.7%[27]. - Long-term borrowings increased significantly to ¥958,577,124.01 from ¥497,490,378.32, representing an increase of 92.7%[27]. - The total liabilities of the company rose to ¥3,230,179,388.11, compared to ¥2,937,125,973.28, reflecting an increase of 10%[27]. - The total equity attributable to shareholders was ¥2,241,356,113.30, slightly down from ¥2,246,791,261.75, a decrease of 0.2%[27]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥379,581,732.41, showing a substantial increase of 122.90%[2]. - Net cash flow from operating activities increased by CNY 209,289,917.59, a growth of 122.90%, primarily driven by improved sales performance and better collection of receivables[14]. - Cash flow from investing activities decreased by CNY 215,661,444.85, a decline of 44.76%, mainly due to reduced payments for fixed assets and investments[15]. - Cash flow from financing activities increased by CNY 492,384,221.41, a growth of 39.23%, primarily due to increased debt repayments and other financing activities[17]. - The cash and cash equivalents at the end of Q3 2024 amounted to ¥725.03 million, up from ¥555.88 million at the end of Q3 2023, reflecting an increase of about 30.5%[32]. - The company incurred a total investment cash outflow of ¥266.18 million, a decrease from ¥481.84 million in Q3 2023, indicating a reduction of approximately 44.8%[32]. - The financing cash inflow for Q3 2024 was ¥1.85 billion, compared to ¥1.69 billion in Q3 2023, showing an increase of about 9.2%[32]. Expenses and Income - The company experienced a 127.31% increase in financial expenses, primarily due to increased bank borrowing and the capitalization of interest expenses[9]. - Income tax expenses increased by CNY 6,216,098.60, a growth of 126.11%, mainly due to the performance growth of subsidiaries[11]. - Other income increased by CNY 262,333.80, a growth of 414.42%, mainly due to deductions from risk deposits of contractors who failed to meet production targets[11]. - Research and development expenses increased to ¥56,656,746.61, compared to ¥45,876,398.38 in the previous year, marking a rise of 23.5%[28]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 30,819[18]. - The largest shareholder, Inner Mongolia Jinhe Holdings Co., Ltd., holds 31.33% of the shares, totaling 241,758,670 shares[18]. - The company has repurchased a total of 15,221,500 shares, accounting for 1.97% of the total share capital, with a total transaction amount of 50,098,780.21 RMB[24]. - The company plans to use self-raised funds to repurchase shares for employee stock ownership plans, with a total repurchase amount between 50 million and 100 million RMB[24]. Other Developments - The company approved the establishment of a research institute in collaboration with Chengdu Agricultural Technology Center on July 17, 2024[21]. - The company has implemented a stock option incentive plan, granting 11.75 million stock options at an exercise price of 2.94 RMB per option[22]. - The company recorded an investment loss of ¥631,039.01 from the disposal of its subsidiary, Animal Nutrition Company[10]. - Net loss from asset impairment increased by CNY 9,904,635.03, a growth of 133.23% compared to the same period last year, mainly due to the decline in market prices of certain veterinary chemical drugs and starch-related products, leading to inventory write-downs[11]. - Other comprehensive income after tax decreased by CNY 18,687,459.87, a decline of 157.13%, primarily due to exchange rate fluctuations affecting the foreign currency financial statements of overseas subsidiaries[12]. Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance growth[28].

证券代码：002688 证券简称：金河生物 公告编号：2024-103 金河生物科技股份有限公司 关于2024年1-9月计提资产减值准备的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 | 项 目 | 2024 年 1-9 月计提金额 | | --- | --- | | 信用减值损失 | 3,572,694.97 | | 其中：应收账款 | 3,264,287.36 | | 其他应收款 | 308,407.61 | | 资产减值损失 | 17,338,597.73 | | 其中：存货 | 17,338,597.73 | | 合 计 | 20,911,292.70 | 二、本次计提减值准备主要项目说明及计提依据 （一）预期信用损失 本公司对于应收票据、应收账款、其他应收款，无论是否存在重大融资成 分，本公司均按照整个存续期的预期信用损失计量损失准备。 一、本次计提资产减值准备情况概述 根据《企业会计准则》、《深圳证券交易所上市公司自律监管指引第 1 号 ——主板上市公司规范运作》相关规定，基于谨慎性原则，金河生物科技股份 有限公司（以下简称"公 ...

关于会计政策变更的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 重要内容提示： 1、金河生物科技股份有限公司（以下简称"公司"）本次会计政策变更是 根据中华人民共和国财政部（以下简称"财政部"）发布的《企业会计准则解释 第 17 号》（财会[2023]21 号，以下简称"《准则解释第 17 号》"）、《企业 会计准则应用指南汇编 2024》（以下简称"《指南汇编 2024》"）的相关规定 进行的变更，无需提交公司董事会和股东大会审议。 2、本次会计政策变更不会对公司财务状况、经营成果等产生重大影响，不 存在损害公司及股东利益的情况。 一、会计政策变更概述 证券代码：002688 证券简称：金河生物 公告编号：2024-100 金河生物科技股份有限公司 1 本次会计政策变更后，公司将按照《准则解释第 17 号》、《指南汇编 2024》 的相关要求执行。除上述政策变更外，其他未变更部分，仍按照财政部前期颁布 的《企业会计准则——基本准则》和各项具体会计准则、企业会计准则应用指南、 企业会计准则解释以及其他相关规定执行。 二、本次会计政策变更对公 ...

金河生物科技股份有限公司（以下简称"公司"）于近日收到控股股东内蒙 古金河控股有限公司（以下简称"金河控股"）的通知，获悉金河控股所持有本 公司的部分股份办理了股票质押式回购交易延期购回业务。具体事项如下： 一、本次股东股票质押式回购交易延期购回基本情况 金河控股于近日办理了股份质押延期手续，将部分质押股份购回日延期至 2025 年 10 月 29 日。本次股份质押延期购回的主要原因是其根据自身资金需求 所做出的安排，不涉及新增融资。详见下表： | | 是否为控 | | | | | 是否 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 第一大股 | | 本次质押数 | 占其所 持股份 | 占公司 总股本 | 为限 | 是否为 补充质 | 质押开始 | | 质押到 | 延期购 回后到 | | 质权人 | 质押 | | 名称 | 东及其一 | | 量（股） | 比例 | 比例 | 售股 | 押 | 日期 | | 期日 | ...